PATENT CLAIM ANALYSIS

Application Number: 15889261
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["514", "009800"]

Abstract:
Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

Claim (Index 9):
A method of treating a patient-subject at 10 weeks of pregnancy or earlier, wherein the patient-subject is suspected of developing incipient preeclampsia, the method comprising:\n (a) determining the level of at least one sialyl Lewis antigen in at least one subject diagnosed with preeclampsia at about 30 weeks of pregnancy or later, said level being a first comparator; (b) determining the level of said at least one sialyl Lewis antigen of step (a) in at least one pregnant non-preeclampsia subject at about 30 weeks of pregnancy or later, said result being a second comparator; (c) determining the level of said sialyl Lewis antigen in the patient-subject; (d) comparing the level of sialyl Lewis antigen of (c) with said first and second comparators; and (e) if the level of the sialyl Lewis antigen determined in step (c) is closer to the level determined in step (a) than the level determined in step (b), administering to said patient-subject a therapeutically effective amount of an agent that prevents, treats or reverses preeclampsia-induced pathologies; thereby treating the patient-subject suspected of developing incipient preeclampsia.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 88.0
- Lexical Diversity: 2.53846
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11131952', '12698395', '11317378', '13180845', '12849651']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7544315453866673
- 35 USC 102 Novelty (BERT): 0.508884446946132
- Combined Prediction Score: 0.7298768355426138
- Mean Citation Score: 233.228884
- Max Citation Score: 239.21918
- Similarity Product: 143.923039893688

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test